SEEDING OF INTRAVASCULAR STENTS WITH GENETICALLY ENGINEERED ENDOTHELIAL CELLS

用基因工程内皮细胞接种血管内支架

• 批准号: 3899254
• 负责人: M B LEON
• 金额: --
• 依托单位: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3899254
• 关键词: antithrombogenic surface; beta galactosidase; genetic manipulation; hybrid cells; implant; molecular biology; plasminogen activator; thrombosis; tissue support frame; vascular endothelium

Stents are being used as a clinical device to maintain an effective internal scaffold within vascular structures. However, the ultimate utility of stent implantation maybe limited by adverse early and late biological responses. Both subacute thrombotic closure after stent placement and neointimal proliferation have resulted in untoward clinical results in some patients. In an effort to improve versatility and function of stents molecular biology techniques are being considered to reduce surface thrombogenicity and evoke more favorable biological responses. Since animal studies have indicated that rapid stent endothelialization markedly reduces early thrombus formation, this study was undertaken to seed metallic stents with genetically engineered endothelial cells incorporating the gene for either bacterial B-galactosidase or human tissue plasminogen activator. This work, supervised and performed in close collaboration with the Molecular Hematology Branch, indicated that seeding stents with genetically engineered endothelial cells was indeed feasible. These preliminary findings suggest the possibility that modification of the stent surface with partial or complete endothelial cell coverage might result in an environment less susceptible to thrombus formation with the potential for local delivery of pharmacologic substances which might ultimately improve stent function.

支架正在被用作一种临床设备，以保持有效的 血管结构内的内部支架。然而，最终的效用 支架置入可能受到早期和晚期不良生物学因素的限制 回应。支架置入后的亚急性血栓闭合和 新生内膜的增殖在某些情况下导致了不良的临床结果。 病人。为了努力提高支架的通用性和功能 分子生物学技术正被考虑用来减少表面 血栓形成，并引起更有利的生物反应。既然是动物 研究表明，快速支架内皮化显著减少 早期血栓的形成，这项研究是为了植入金属支架 用基因工程内皮细胞整合了 细菌B-半乳糖苷酶或人类组织纤溶酶原激活剂。 这项工作是在监督和执行这项工作的情况下与 分子血液学分会指出，植入支架的基因 工程化内皮细胞确实是可行的。这些初步的 研究结果表明，支架表面的修饰有可能 部分或全部内皮细胞覆盖可能会导致 不易形成血栓的环境，具有潜在的 药理物质的本地输送，最终可能会改善 支架功能。